Arsia Therapeutics signs biggest deal, this one with Biogen for subcutaneous biologics

Arsia Therapeutics, a Cambridge, USA-based start-up company, today announced a major collaboration with biotech giant Biogen (Nasdaq: BIIB).

The deal is the largest announced to date leveraging Arsia’s pioneering work in the area of formulation development of protein pharmaceuticals and monoclonal antibodies. The company, founded in 2013, is venture backed by Polaris Partners and has so far entered a dozen or so much small collaborations.

Arsia and Biogen will focus on providing meaningful treatment administration improvements for hemophilia patients by enabling subcutaneous versions of treatments that are currently administered via intravenous infusion. The companies will combine expertise to research formulations that could be administered at home through convenient subcutaneous injections. As part of the collaboration, Biogen will also utilize Arsia’s patented formulation technology, which has broad based utility for the production of high-concentration subcutaneous dose forms of protein and antibody drugs critical for next-generation biologics.